UK guidelines agreed for economic evaluation of medicines Newsletter Article 16 February 2013 Pages: 6 - 6
Condemning age discrimination in Britain’s health service Newsletter Article 16 February 2013 Pages: 5 - 5
Questioning the credibility of clinical & economic analyses Newsletter Article 16 February 2013 Pages: 4 - 4
Beyond safety and efficacy - meeting the needs of decision makers Katherine V Mann Newsletter Article 16 February 2013 Pages: 3 - 5
Keys to conducting a credible pharmacoeconomic study Katherine V Mann Newsletter Article 16 February 2013 Pages: 3 - 4
Overcoming healthcare inequalities - ambitious aims for WHO? Newsletter Article 16 February 2013 Pages: 16 - 16
SmithKline Beecham and Pfizer follow Merck’s earlier lead … Newsletter Article 16 February 2013 Pages: 15 - 15
Long-term limitations in survivors of Hodgkin’s disease Newsletter Article 16 February 2013 Pages: 12 - 12
Enhance the drug evaluation process with a new model Newsletter Article 16 February 2013 Pages: 12 - 13
Iododoxorubicin disappoints in metastatic breast cancer Newsletter Article 16 February 2013 Pages: 12 - 12
Prophylaxis increases QALYs for membraneous nephropathy Newsletter Article 16 February 2013 Pages: 11 - 11
Cutting nosocomial pneumonia costs with new methodology Newsletter Article 16 February 2013 Pages: 10 - 11
Maintenance therapy with sertraline ‘a cost-effective strategy’ Newsletter Article 16 February 2013 Pages: 11 - 11
Simple clinical data - the key to early discharge after MI? Newsletter Article 16 February 2013 Pages: 10 - 10
Medication review service reduces healthcare utilisation Newsletter Article 16 February 2013 Pages: 10 - 10
The impact of a preferred drugs list - New Zealand’s experience Newsletter Article 16 February 2013 Pages: 9 - 9
Canadian prescribing of zidovudine falls after Concorde Newsletter Article 16 February 2013 Pages: 9 - 9
